Longeveron (LGVN) Notes Payables (2021 - 2023)
Longeveron's (LGVN) quarterly Notes Payables came in at $457000.0 in Q1 2023, down 73.9% quarter-over-quarter from $1.8 million in Q4 2022.
Longeveron (LGVN) Notes Payables (2021 - 2023) Analysis & Trends
Longeveron's Notes Payables history runs 3 years deep, the most recent figure standing at $457000.0 for Q1 2023.
- On a quarterly basis, Notes Payables changed N/A year-over-year to $457000.0 in Q1 2023; TTM through Mar 2023 was $457000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $1.8 million, up 171.47% from the prior year.
- Notes Payables slipped to $457000.0 in Q1 2023 per LGVN's latest filing, from $1.8 million in the prior quarter.
- Across five years, Notes Payables topped out at $1.8 million in Q4 2022 and bottomed at $457000.0 in Q1 2023.
- The 3-year median for Notes Payables is $645000.0 (2021), against an average of $951000.0.
- Biggest YoY gain for Notes Payables was 171.47% in 2022; the steepest drop was 171.47% in 2022.
- Year by year, Notes Payables stood at $645000.0 in 2021, then jumped by 171.47% to $1.8 million in 2022, then plunged by 73.9% to $457000.0 in 2023.
- Per Business Quant, the three latest LGVN Notes Payables figures stand at $457000.0 (Q1 2023), $1.8 million (Q4 2022), and $645000.0 (Q4 2021).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 457,000.00 |
| Dec 31, 2022 | 1.75 Mn |
| Dec 31, 2021 | 645,000.00 |